Lipids in Hepatic Glycogen Storage Diseases: Pathophysiology, Monitoring of Dietary Management and Future Directions

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2015 Jan 31

PMID 25633903

Citations 26

Authors

Terry G J Derks

Margreet van Rijn

Affiliations

Soon will be listed here.

Abstract

Hepatic glycogen storage diseases (GSD) underscore the intimate relationship between carbohydrate and lipid metabolism. The hyperlipidemias in hepatic GSD reflect perturbed intracellular metabolism, providing biomarkers in blood to monitor dietary management. In different types of GSD, hyperlipidemias are of a different origin. Hypertriglyceridemia is most prominent in GSD type Ia and associated with long-term outcome morbidity, like pancreatitis and hepatic adenomas. In the ketotic subtypes of GSD, hypertriglyceridemia reflects the age-dependent fasting intolerance, secondary lipolysis and increased mitochondrial fatty acid oxidation. The role of high protein diets is established for ketotic types of GSD, but non-traditional dietary interventions (like medium-chain triglycerides and the ketogenic diet) in hepatic GSD are still controversial and necessitate further studies. Patients with these rare inherited disorders of carbohydrate metabolism meet several criteria of the metabolic syndrome, therefore close monitoring for cardiovascular diseases in ageing GSD patients may be justified.

Citing Articles

A machine learning model accurately identifies glycogen storage disease Ia patients based on plasma acylcarnitine profiles.

Groen J, de Haan B, Overduin R, Haijer-Schreuder A, Derks T, Heiner-Fokkema M Orphanet J Rare Dis. 2025; 20(1):15.

PMID: 39789579 PMC: 11721056. DOI: 10.1186/s13023-025-03537-2.

Medium-Chain Triglyceride Oil and Dietary Intervention Improved Body Composition and Metabolic Parameters in Children with Glycogen Storage Disease Type 1 in Jordan: A Clinical Trial.

Subih H, Qudah R, Janakat S, Rimawi H, Elsahoryi N, Alyahya L Foods. 2024; 13(7).

PMID: 38611395 PMC: 11011708. DOI: 10.3390/foods13071091.

Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care.

Rossi A, Simeoli C, Pivonello R, Salerno M, Rosano C, Brunetti B Rev Endocr Metab Disord. 2024; 25(4):707-725.

PMID: 38556561 PMC: 11294274. DOI: 10.1007/s11154-024-09880-2.

Dietary Inflammatory Potential in Pediatric Diseases: A Narrative Review.

Tosi M, Montanari C, Bona F, Tricella C, Agostinelli M, Dolor J Nutrients. 2023; 15(24).

PMID: 38140353 PMC: 10745369. DOI: 10.3390/nu15245095.

Severe perioperative lactic acidosis in a pediatric patient with glycogen storage disease type Ia: a case report.

Takahashi T, Oue K, Imado E, Doi M, Shimizu Y, Yoshida M JA Clin Rep. 2023; 9(1):91.

PMID: 38114842 PMC: 10730783. DOI: 10.1186/s40981-023-00683-z.

References

Huidekoper H, Visser G, Ackermans M, Sauerwein H, Wijburg F . A potential role for muscle in glucose homeostasis: in vivo kinetic studies in glycogen storage disease type 1a and fructose-1,6-bisphosphatase deficiency. J Inherit Metab Dis. 2010; 33(1):25-31. PMC: 2828550. DOI: 10.1007/s10545-009-9030-9. View

Fernandes J, PIKAAR N . Hyperlipemia in children with liver glycogen disease. Am J Clin Nutr. 1969; 22(5):617-27. DOI: 10.1093/ajcn/22.5.617. View

White F, Jones S . The use of continuous glucose monitoring in the practical management of glycogen storage disorders. J Inherit Metab Dis. 2011; 34(3):631-42. DOI: 10.1007/s10545-011-9335-3. View

Huidekoper H, Ackermans M, Ruiter A, Sauerwein H, Wijburg F . Endogenous glucose production from infancy to adulthood: a non-linear regression model. Arch Dis Child. 2014; 99(12):1098-102. DOI: 10.1136/archdischild-2013-305718. View

Ubels F, Rake J, Slaets J, Smit G, Smit A . Is glycogen storage disease 1a associated with atherosclerosis?. Eur J Pediatr. 2002; 161 Suppl 1:S62-4. DOI: 10.1007/s00431-002-1006-9. View

Bernier A, Sentner C, Correia C, Theriaque D, Shuster J, Smit G . Hyperlipidemia in glycogen storage disease type III: effect of age and metabolic control. J Inherit Metab Dis. 2008; 31(6):729-32. PMC: 3832627. DOI: 10.1007/s10545-008-0919-5. View

Valayannopoulos V, Bajolle F, Arnoux J, Dubois S, Sannier N, Baussan C . Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res. 2011; 70(6):638-41. DOI: 10.1203/PDR.0b013e318232154f. View

Rake J, Visser G, Labrune P, Leonard J, Ullrich K, Smit G . Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002; 161 Suppl 1:S20-34. DOI: 10.1007/s00431-002-0999-4. View

Bernier A, Correia C, Haller M, Theriaque D, Shuster J, Weinstein D . Vascular dysfunction in glycogen storage disease type I. J Pediatr. 2008; 154(4):588-91. PMC: 3607442. DOI: 10.1016/j.jpeds.2008.10.048. View

10.

Kasapkara C, Cinasal Demir G, Hasanoglu A, Tumer L . Continuous glucose monitoring in children with glycogen storage disease type I. Eur J Clin Nutr. 2013; 68(1):101-5. DOI: 10.1038/ejcn.2013.186. View

11.

Brambilla A, Mannarino S, Pretese R, Gasperini S, Galimberti C, Parini R . Improvement of Cardiomyopathy After High-Fat Diet in Two Siblings with Glycogen Storage Disease Type III. JIMD Rep. 2014; 17:91-5. PMC: 4241197. DOI: 10.1007/8904_2014_343. View

12.

Wang D, Fiske L, Carreras C, Weinstein D . Natural history of hepatocellular adenoma formation in glycogen storage disease type I. J Pediatr. 2011; 159(3):442-6. PMC: 3135733. DOI: 10.1016/j.jpeds.2011.02.031. View

13.

KELSCH R, Oliver W . Studies on dietary correction of metabolic abnormalities in hepatorenal glycogenosis. Pediatr Res. 1969; 3(2):160-70. DOI: 10.1203/00006450-196903000-00008. View

14.

Xue J, Chen H, Xiong D, Huang G, Ai H, Liang Y . Noninvasive measurement of glucose in artificial plasma with near-infrared and Raman spectroscopy. Appl Spectrosc. 2014; 68(4):428-33. DOI: 10.1366/13-07250. View

15.

Grefhorst A, Schreurs M, Oosterveer M, Cortes V, Havinga R, Herling A . Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor α (LXRα) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1. Biochem J. 2010; 432(2):249-54. DOI: 10.1042/BJ20101225. View

16.

Bandsma R, Prinsen B, van Der Velden M, Rake J, Boer T, Smit G . Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res. 2008; 63(6):702-7. DOI: 10.1203/PDR.0b013e31816c9013. View

17.

Burr I, ONeill J, Karzon D, Howard L, Greene H . Comparison of the effects of total parenteral nutrition, continuous intragastric feeding, and portacaval shunt on a patient with type I glycogen storage disease. J Pediatr. 1974; 85(6):792-5. DOI: 10.1016/s0022-3476(74)80342-2. View

18.

Smit G, Berger R, Potasnick R, Moses S, Fernandes J . The dietary treatment of children with type I glycogen storage disease with slow release carbohydrate. Pediatr Res. 1984; 18(9):879-81. DOI: 10.1203/00006450-198409000-00015. View

19.

Cuttino Jr J, SUMMER G, Hill Jr H, Mitchell B . Response to medium chain triglycerides in von Gierke's disease. Pediatrics. 1970; 46(6):925-9. View

20.

Shah K, ODell S . Effect of dietary interventions in the maintenance of normoglycaemia in glycogen storage disease type 1a: a systematic review and meta-analysis. J Hum Nutr Diet. 2013; 26(4):329-39. DOI: 10.1111/jhn.12030. View